CEO Conley Chee was paid $1,041,697 in fiscal year 2023 (SEC filing 0001193125-24-105876 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$1,436,782 Nancy Simonian total, FY2023 Former President & Chief Executive Officer — highest-paid officer; CEO Conley Chee: $1,041,697 | — CEO (Conley Chee) pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Ask our research desk, 24h, every figure cited to its filing.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Nancy Simonian | $635,385 | $0 | $477,174 | $0 | $318,986 | $0 | $5,237 | $1,436,782 |
| Former President & Chief Executive Officer | ||||||||
| Conley Chee | 479,092 | 0 | 369,460 | 0 | 192,455 | 0 | 690 | 1,041,697 |
| President & Chief Executive Officer | ||||||||
| Eric Olson | 409,791 | 0 | 140,700 | 0 | 0 | 0 | 385,277 | 935,768 |
| Former Chief Scientific Officer | ||||||||
| David Roth | 516,154 | 0 | 160,800 | 0 | 197,600 | 0 | 1,980 | 876,534 |
| Chief Medical Officer | ||||||||
| Jason Haas | 485,185 | 0 | 160,800 | 0 | 185,744 | 0 | 1,290 | 833,019 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Nancy Simonian | $1,436,782 | $3,487,880 | — | ↓ −2,051,098 |
| Conley Chee | 1,041,697 | — | — | — |
| Eric Olson | 935,768 | 1,668,669 | — | ↓ −732,901 |
| David Roth | 876,534 | 1,759,093 | — | ↓ −882,559 |
| Jason Haas | 833,019 | 1,416,010 | — | ↓ −582,991 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Syros Pharmaceuticals, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper SYRS reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses SYRS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Conley Chee | RSU | 2023-02-16 | — | — | 35,000 | — | — |
| Conley Chee | PSU | 2023-02-16 | — | 35,000 | — | — | 369,460 |
| Conley Chee | RSU | 2023-12-02 | — | — | 86,000 | — | — |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Conley Chee | $0 | $369,460 | $0 | 100.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| David Roth | RSU | 6,000 | — | $46,740 |
| Conley Chee | Option | 15,752 | 48.1 | — |
| Eric Olson | Option | 3,477 | 30.38 | — |
| Nancy Simonian | RSU | 118,700 | — | 924,673 |
| Conley Chee | RSU | 6,000 | — | 46,740 |
| Eric Olson | Option | 6,069 | 114.1 | — |
| Nancy Simonian | PSU | 118,700 | — | 924,673 |
| Jason Haas | RSU | 40,000 | — | 311,600 |
| Eric Olson | Option | 453 | 13.88 | — |
| Nancy Simonian | RSU | 40,000 | — | 311,600 |
| David Roth | RSU | 20,000 | — | 155,800 |
| David Roth | RSU | 18,875 | — | 147,036 |
| Eric Olson | Option | 7,499 | 109 | — |
| Conley Chee | RSU | 86,000 | — | 669,940 |
| David Roth | RSU | 40,000 | — | 311,600 |
| Nancy Simonian | RSU | 18,000 | — | 140,220 |
| David Roth | Option | 24,875 | 6.73 | — |
| Conley Chee | Option | 5,420 | 15.9 | — |
| Jason Haas | RSU | 18,875 | — | 147,036 |
| Eric Olson | Option | 7,499 | 67.1 | — |
| David Roth | Option | 396 | 75.4 | — |
| Conley Chee | Option | 22,250 | 6.73 | — |
| David Roth | Option | 3,471 | 114.1 | — |
| Nancy Simonian | RSU | 40,125 | — | 312,574 |
| Eric Olson | Option | 2,584 | 30.4 | — |
| David Roth | PSU | 40,000 | — | 311,600 |
| Conley Chee | PSU | 86,000 | — | 669,940 |
| Jason Haas | PSU | 40,000 | — | 311,600 |
| Nancy Simonian | Option | 20,314 | 15.9 | — |
| Conley Chee | RSU | 35,000 | — | 272,650 |
| Conley Chee | PSU | 35,000 | — | 272,650 |
| Conley Chee | RSU | 17,000 | — | 132,430 |
| Jason Haas | RSU | 6,000 | — | 46,740 |
| Jason Haas | Option | 6,775 | 15.9 | — |
| David Roth | Option | 6,775 | 15.9 | — |
| Jason Haas | Option | 34,382 | 45.4 | — |
| Jason Haas | Option | 24,875 | 6.73 | — |
| Nancy Simonian | Option | 57,500 | 6.73 | — |
| Eric Olson | Option | 6,349 | 109 | — |
| Eric Olson | Option | 8,415 | 75.4 | — |
| Eric Olson | Option | 3,955 | 15.9 | — |
The company aims to reward value creation for stockholders and attract, motivate, and retain executive officers by aligning their interests with those of stockholders through a mix of short-term and long-term performance-based incentives. The compensation committee considers market comparables, individual and corporate performance, and the desire to foster long-term commitment while managing dilution.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Peter WirthIndependent | $80,000 | $14,800 | $15,604 | — | $110,404 | $110,404 |
| Marsha H. FanucciIndependent | 54,375 | 14,800 | 15,604 | — | 84,779 | 84,779 |
| S. Gail EckhardtIndependent | 52,000 | 14,800 | 15,604 | — | 82,404 | 82,404 |
| Richard A. YoungIndependent | 51,750 | 14,800 | 15,604 | — | 82,154 | 82,154 |
| Deborah DunsireIndependent | 48,670 | 14,800 | 15,604 | — | 79,074 | 79,074 |
| Andrew M. OhIndependent | 48,125 | 14,800 | 15,604 | — | 78,154 | 78,154 |
| Timothy C. TysonIndependent | 45,625 | 14,800 | 15,604 | — | 76,029 | 76,029 |
| Mark J. AllesIndependent | 35,625 | 14,800 | 15,604 | — | 66,029 | 66,029 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $416,170 |
| Equity awards (grant-date value) | $118,400 |
| All other compensation | $659,027 |
| Total cost of the board | $1,193,597 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Syros Pharmaceuticals, Inc. | 2023 | Conley Chee | $479,092 | $369,460 | $0 | $192,455 | $1,041,697 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Nancy Simonian | 10-K | 2024-04-23 | 0001193125-24-105876 | Section “Executive Compensation”. As printed: 1,436,782. Filing ↗machine: r10 · c27 · span 257487–257496 |
| 2 | Section 01, Conley Chee | 10-K | 2024-04-23 | 0001193125-24-105876 | Section “Executive Compensation”. As printed: 1,041,697. Filing ↗machine: r2 · c27 · span 248160–248169 |
| 3 | Section 01, Eric Olson | 10-K | 2024-04-23 | 0001193125-24-105876 | Section “Executive Compensation”. As printed: 935,768. Filing ↗machine: r12 · c27 · span 260263–260270 |
| 4 | Section 01, David Roth | 10-K | 2024-04-23 | 0001193125-24-105876 | Section “Executive Compensation”. As printed: 876,534. Filing ↗machine: r4 · c27 · span 250575–250582 |
| 5 | Section 01, Jason Haas | 10-K | 2024-04-23 | 0001193125-24-105876 | Section “Executive Compensation”. As printed: 833,019. Filing ↗machine: r6 · c27 · span 253235–253242 |
| 6 | Section 03, Conley Chee RSU | 10-K | 2024-04-23 | 0001193125-24-105876 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 7 | Section 03, Conley Chee PSU | 10-K | 2024-04-23 | 0001193125-24-105876 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 8 | Section 03, Conley Chee RSU | 10-K | 2024-04-23 | 0001193125-24-105876 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 9 | Section 08, Peter Wirth | 10-K | 2024-04-23 | 0001193125-24-105876 | Section “Director Compensation”. As printed: 110,404. Filing ↗ |
| 10 | Section 08, Marsha H. Fanucci | 10-K | 2024-04-23 | 0001193125-24-105876 | Section “Director Compensation”. As printed: 84,779. Filing ↗ |
| 11 | Section 08, S. Gail Eckhardt | 10-K | 2024-04-23 | 0001193125-24-105876 | Section “Director Compensation”. As printed: 82,404. Filing ↗ |
| 12 | Section 08, Richard A. Young | 10-K | 2024-04-23 | 0001193125-24-105876 | Section “Director Compensation”. As printed: 82,154. Filing ↗ |
| 13 | Section 08, Deborah Dunsire | 10-K | 2024-04-23 | 0001193125-24-105876 | Section “Director Compensation”. As printed: 79,074. Filing ↗ |
| 14 | Section 08, Andrew M. Oh | 10-K | 2024-04-23 | 0001193125-24-105876 | Section “Director Compensation”. As printed: 78,154. Filing ↗ |
| 15 | Section 08, Timothy C. Tyson | 10-K | 2024-04-23 | 0001193125-24-105876 | Section “Director Compensation”. As printed: 76,029. Filing ↗ |
| 16 | Section 08, Mark J. Alles | 10-K | 2024-04-23 | 0001193125-24-105876 | Section “Director Compensation”. As printed: 66,029. Filing ↗ |
| 17 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 18 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 19 | Section 09b board cost (computed) | Computed | — | — | Cash 416,170 + equity 118,400 + all other 659,027 = 1,193,597, summed across the director compensation table rows.machine: formula: Σ = 1,193,597 |
| 20 | Syros Pharmaceuticals, Inc. (subject), Section 10b CEO total | 10-K | 2024-04-23 | 0001193125-24-105876 | CEO total compensation as printed in Syros Pharmaceuticals, Inc.'s own proxy. As printed: 1,041,697. Filing ↗machine: r2 · c27 · span 248160–248169 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat